KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $58.5 billion.

  • Gilead Sciences' Liabilities and Shareholders Equity rose 735.08% to $58.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $229.7 billion, marking a year-over-year increase of 139.59%. This contributed to the annual value of $59.0 billion for FY2024, which is 503.82% down from last year.
  • According to the latest figures from Q3 2025, Gilead Sciences' Liabilities and Shareholders Equity is $58.5 billion, which was up 735.08% from $55.7 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Liabilities and Shareholders Equity ranged from a high of $68.0 billion in Q2 2021 and a low of $53.6 billion during Q2 2024
  • For the 5-year period, Gilead Sciences' Liabilities and Shareholders Equity averaged around $61.3 billion, with its median value being $62.3 billion (2023).
  • In the last 5 years, Gilead Sciences' Liabilities and Shareholders Equity soared by 2154.32% in 2021 and then crashed by 1404.94% in 2024.
  • Quarter analysis of 5 years shows Gilead Sciences' Liabilities and Shareholders Equity stood at $68.0 billion in 2021, then decreased by 7.04% to $63.2 billion in 2022, then fell by 1.66% to $62.1 billion in 2023, then decreased by 5.04% to $59.0 billion in 2024, then decreased by 0.78% to $58.5 billion in 2025.
  • Its last three reported values are $58.5 billion in Q3 2025, $55.7 billion for Q2 2025, and $56.4 billion during Q1 2025.